Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 24001 AL 24015

Usefulness of Cerebrospinal Fluid Alzheimer's disease biomarkers in older patients: Evidence from a national multicenter prospective study

Decaix T, Mouton-Liger F, Dumurgier J, Cognat E, Vrillon A, Hugon J, Hourregue C, Bouaziz-Amar E, Wallon D, Muraine MQ, Troussière AC, Magnin E, Duron E, Philippi N, Blanc F, Gabelle A, Croisile B, Jager A, Pasquier F, Schraen S, Sayette V, Beaufils É, Miguet-Alfonsi C, Paquet C, Lilamand M.

J Prev Alzheimers Dis. 2025 Jan;12(1):100009. doi: 10.1016/j.tjpad.2024.100009. Epub 2025 Jan 1.

Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials

Abushakra S, Doraiswamy PM, Hey JA, Tosun D, Barkhof F, Barakos J, Petrella J, Kesslak JP, Power A, Sabbagh M, Porsteinsson A, Cohen S, Gauthier S, Ritchie C, Watson D, McSweeney E, Boada M, Liang E, Bracoud L, McLaine R, Flint S, Schaefer JF, Yu J, Bray M, Hendrix S, Dickson S, Durrant A, Albayrak A, Tolar M.

CNS Drugs. 2026 Feb;40(2):199-214. doi: 10.1007/s40263-025-01251-y. Epub 2025 Dec 1.

The Evaluation of Clinical Applications for the Detection of the Alzheimer's Disease Biomarker GFAP

Ozcelikay-Akyildiz G, Karadurmus L, Cetinkaya A, Uludag İ, Ozcan B, Unal MA, Sezginturk MK, Ozkan SA.

Crit Rev Anal Chem. 2025;55(8):1690-1701. doi: 10.1080/10408347.2024.2393874. Epub 2024 Aug 23.

Brain health clinics - An evolving clinical pathway?

Butters AF, Blackman J, Farouk H, Meky S, A Newson M, Lemke T, Rosewell N, Selwood JA, Turner NL, Coulthard EJ, Archer HA.

J Prev Alzheimers Dis. 2025 Mar;12(3):100051. doi: 10.1016/j.tjpad.2024.100051. Epub 2025 Feb 3.

Evaluating amyloid-beta as a surrogate endpoint in trials of anti-amyloid-beta drugs in Alzheimer's disease: a Bayesian meta-analysis

Ren S, Singh J, Gsteiger S, Cogley C, Reed B, Abrams KR, Dawoud D, Owen RK, Tappenden P, Quinn TJ, Bujkiewicz S.

J Comp Eff Res. 2026 Jan;15(1):e250095. doi: 10.57264/cer-2025-0095. Epub 2025 Dec 2.

PDE5 Inhibitors as Modulators of Alzheimer's-Associated Inflammation and Oxidative Stress: A Meta-Analytical Assessment of Preclinical Studies

Uppuluri CT, Prasad YSKV, Asadi K, Kumari TP, Pelluri R, Chakravarthi G, Nalluri BN, Gurram PC.

Mol Neurobiol. 2025 Dec 23;63(1):322. doi: 10.1007/s12035-025-05635-5.

Alternative TMA-93 version demonstrates comparable performance and discriminative accuracy in early Alzheimer's disease

Arriola-Infante JE, García-Roldán E, García-Solís D, Lojo-Ramírez JA, Marín-Cabañas AM, Luque-Tirado A, Almodóvar-Sierra Á, Bernal Sánchez-Arjona M, Maillet D, Franco-Macías E.

J Alzheimers Dis. 2025 Dec;108(3):1347-1356. doi: 10.1177/13872877251386479. Epub 2025 Oct 16.

Exploring the gut-brain-microbiome axis in Alzheimer's disease: Integrating metagenomics, metabolomics, and artificial intelligence for next-generation biomarker discovery

Oso TA, Ahmed MM, Okesanya OJ, Adebayo UO, Obadeyi KB, Othman ZK, Lucero-Prisno DE 3rd.

J Alzheimers Dis. 2026 Feb;109(4):1542-1557. doi: 10.1177/13872877251407700. Epub 2025 Dec 29.

Exploring precision medicine by utilizing individual genetic information for the management of Alzheimer's disease

Kanda A, Rani A, Mazumder A.

Pharmacogenomics. 2025 Jul-Aug;26(10-12):455-474. doi: 10.1080/14622416.2025.2560296. Epub 2025 Sep 15.

Understanding Cerebral Blood Flow Dynamics for Alzheimer's Disease Prevention Through Acute Exercise (flADex): Protocol for a Randomized Crossover Trial

Martín-Fuentes I, Fernandez-Gamez B, Vidal-Almela S, Caro-Rus A, Solis-Urra P, Sánchez-Aranda L, Fernández-Ortega J, Sanchez-Martinez J, Coca-Pulido A, Olvera-Rojas M, Barranco-Moreno EJ, Marin-Alvarez JD, Bakker EA, Toval A, Bellón D, Sclafani A, Karikari TK, Erickson KI, Gómez-Río M, Ortega FB, Esteban-Cornejo I.

Brain Behav. 2025 Nov;15(11):e70636. doi: 10.1002/brb3.70636.

Molecular Biomarkers for Early Detection of Alzheimer's Disease and the Complementary Role of Engineered Nanomaterials: A Systematic Review

Zia Ul Haq M, Zhao X, Obeng Apori S, Singh B, Tian F.

Int J Mol Sci. 2025 Sep 23;26(19):9282. doi: 10.3390/ijms26199282.

Electrochemical Biosensors Combined with Nanomaterial Signal Amplification for the Detection of Alzheimer's Disease Biomarkers in Blood

Peng L, Xie X, Chen X, Chen C.

ACS Sens. 2025 Sep 26;10(9):6380-6405. doi: 10.1021/acssensors.5c02453. Epub 2025 Sep 8.

Influence of age and sex on presymptomatic phases of neurodegenerative diseases: Focus on multiple sclerosis and Alzheimer's disease

Zeydan B, Kantarci K.

Rev Neurol (Paris). 2025 Nov;181(9):829-838. doi: 10.1016/j.neurol.2025.06.015. Epub 2025 Aug 6.

Examining the role of antioxidant supplementation in mitigating oxidative stress markers in Alzheimer's disease: a comprehensive review

Jawad M, Uthirapathy S, Altalbawy FMA, Oghenemaro EF, Rizaev J, Lal M, Eldesoqui M, Sharma N, Pramanik A, Al-Hamairy AK.

Inflammopharmacology. 2025 Feb;33(2):573-592. doi: 10.1007/s10787-024-01622-9. Epub 2024 Dec 19.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias